Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00781612 (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
An Extension Study of Trastuzuma Emtansine in Patients Previously Treated With Trastuzuma Emtansine (NCT00781612)

Trial Description
This is a global, multicenter, open-label extension study. Patients receiving single-agent ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) or combination T-DM1 administered in combination with paclitaxel (Abraxane®; Celgene Corp.) or with pertuzumab (Perjeta®; Genentech, Inc.) ± paclitaxel in a Genentech/Roche-sponsored study who completed the parent study or who continue to receive study drug(s) at the time of the parent study closure are eligible for continued treatment on this protocol.

This trial is sponsored by Genentech, Inc. [1]

Study Data

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 30, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar